
ACET Stock Forecast & Price Target
ACET Analyst Ratings
Bulls say
Adicet Bio Inc's innovative approach to developing allogeneic gamma delta T cell therapies positions the company favorably within the biotechnology sector, particularly with its lead candidate ADI-001 showing promising efficacy in treating autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. The anticipated Phase 1 study of ADI-212 for metastatic castration-resistant prostate cancer, set to begin in 2026, may further expand the company's oncology portfolio, potentially enhancing its market presence. Additionally, Adicet's strategy to contract third-party manufacturers for commercial-scale production is expected to mitigate manufacturing risks, thereby strengthening its operational efficiency and overall market appeal.
Bears say
Adicet Bio Inc. faces a challenging financial outlook, projecting a net loss of $1.13 per share for 2025 due to various risks associated with its lead product candidate, ADI-001. Concerns about the lower efficacy of ADI-001 in patients with prior anti-CD20 therapy failures, alongside heightened competition, may adversely impact market share and revenue potential. The company also confronts significant regulatory hurdles, having not yet obtained FDA approval for its gamma delta T-cell therapies, compounded by lowered success probabilities for its other candidates and increased discount rates reflecting a more conservative stance on future financial performance.
This aggregate rating is based on analysts' research of Adicet Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
ACET Analyst Forecast & Price Prediction
Start investing in ACET
Order type
Buy in
Order amount
Est. shares
0 shares